News

Joseph Papa, chairman and CEO of Perrigo, said: “The acquisition of JB Laboratories will further expand our high-quality manufacturing base and provide additional FDA-approved production capacity to help

The Phase IIa randomized, placebo controlled clinical trial will evaluate the safety and immunogenicity of different doses of its seasonal influenza virus-like particle (VLP) vaccine. Specifically, the vaccine

The company completed its open-label, 24-week, multi-center study to assess the safety of oral glycopyrrolate liquid for the treatment of chronic, moderate-to-severe drooling in pediatric patients three to

The transaction is subject to customary conditions, including the tender of a majority of the outstanding shares of Datascope common stock into the tender offer, regulatory approvals and

In this role Ms Wolf will be responsible for all of Vision-Sciences’s financial operations and business development activities. Before joining Vision-Sciences, Ms Wolf was a managing director at

Most recently, Mr Paulson served as president and CEO of Restore Medical, where he led the company through the commercialization of its Pillar implant technology, its initial public

Pfizer has previously announced that it would stop marketing Exubera inhalation powder because it did not meet customers’ needs or Pfizer’s financial expectations. Since that time, Exubera patients

As a result, Epix will receive $500,000 from Cystic Fibrosis Foundation Therapeutics (CFFT), bringing the total amount of milestone payments achieved under this collaboration to $4.5 million. The

The patent runs until at least April 2025 (subject to any patent term extension that may be available). Geron’s GRNCM1 program is developing human embryonic stem cell (hESC)-derived